300858 科拓生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.8085.2045.3575.4518.250
总资产报酬率 ROA (%)0.7394.8055.0655.1917.760
投入资产回报率 ROIC (%)0.7995.1375.2685.3618.085

边际利润分析
销售毛利率 (%)45.41051.50358.25254.58251.975
营业利润率 (%)20.02628.58636.15134.28734.558
息税前利润/营业总收入 (%)15.71022.98827.85826.26233.175
净利润/营业总收入 (%)17.59125.83031.16231.23929.767

收益指标分析
经营活动净收益/利润总额(%)100.79992.05683.94387.84889.411
价值变动净收益/利润总额(%)16.5413.6605.1387.2377.433
营业外收支净额/利润总额(%)0.010-0.745-0.583-0.549-1.529

偿债能力分析
流动比率 (X)7.7337.6599.92516.29615.560
速动比率 (X)7.4117.2959.44115.62714.963
资产负债率 (%)8.3628.7226.5794.2595.308
带息债务/全部投入资本 (%)-1.524-1.556-0.0800.7370.966
股东权益/带息债务 (%)-6,486.958-6,359.979-122,902.59313,323.43710,189.120
股东权益/负债合计 (%)1,095.8431,046.5811,419.9552,247.7411,783.798
利息保障倍数 (X)-3.638-4.267-3.446-3.350-38.431

营运能力分析
应收账款周转天数 (天)78.25861.75372.447101.453106.466
存货周转天数 (天)82.21394.396122.204119.403105.367